Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471
Yu Rao · 2026
Read Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471 by Yu Rao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242623.txt.
Description
Yu Rao wrote a short piece marking the first approval of a PROTAC drug. It appeared in Cancer Innovation in 2026. On May 1, 2026, United States officials approved vepdegestrant, sold as Veppanu, for some advanced breast cancers with ESR1 changes. Arvinas built the drug with Pfizer after more than twenty years of work.
Most drugs block a protein only while they sit on it. A PROTAC instead tags its target so the cell destroys it. Rao argues the approval proves this event-driven idea can pass review and reach the market. It also gives the many degrader drugs now in testing a path to point to. He sets degraders beside antibodies, gene therapies, and RNA drugs as one more small-molecule tool. For Rao, a lab idea has become a real treatment.
Catalog record
| CREATOR | Yu Rao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |